TNFSF10 and neoplasm: In a previous study, using the same KMS-11 tumor model, we have demonstrated that human CD34+ cells engineered to express membrane-bound TRAIL (CD34−TRAIL+ cells) target not only tumor cells, but also tumor vasculature25.